plinabulin Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Plinabulin is a small molecule under development by BeyondSpring Pharmaceuticals, and is in a world-wide Phase 3 clinical trial for non-small cell lung cancer. Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia and for anti-cancer effects in combination with immune checkpoint inhibitors and in KRAS mutated tumors.   Wikipedia

Chemistry

  • SMILES: CC(C)(C)c1[nH]cnc1\C=C\2/NC(=O)\C(=C\c3ccccc3)\NC2=O
  • InChIKey: UNRCMCRRFYFGFX-TYPNBTCFSA-N
  • Mol. Mass: 336.4
  • ALogP: 0.74
  • ChEMBL Molecule:
    plinabulin  
More Chemistry

Pharmacology

Alternative names

npi2358 | npi 2358 | npi-2358 | plinabulin

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Mutation (Phase 2)

Neoplasms (Phase 2)

Oncogenes (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Translocation, Genetic (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue